69 results
Page 3 of 4
8-K
EX-99.1
r93o a7o5gbve
21 Jun 21
Regulation FD Disclosure
8:15am
8-K
ecu77c93auzxo1x
21 Jun 21
Regulation FD Disclosure
8:15am
S-3ASR
90e2 egiq48m4
18 May 21
Automatic shelf registration
6:01am
8-K
EX-99.1
99h84x i1g7n0psr
13 May 21
Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
7:18am
8-K
nszq0h8wh77d61mqgz
22 Mar 21
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
4:05pm
8-K
EX-99.2
3dw3hh
22 Mar 21
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
4:05pm
8-K
EX-99.1
2w5k7xdvra8i
22 Mar 21
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
4:05pm
8-K
EX-99.1
lmi4q5h0
16 Mar 21
Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
8:10am
8-K
EX-99.1
2130l0tg7
11 Jan 21
A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. JP Morgan Presentation January 2021
7:01am
8-K
EX-99.1
hw79bgt5ecaxc5e
16 Nov 20
A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. Corporate Presentation November 2020
6:30am
8-K
EX-99.1
a5rgbuuu
12 Nov 20
Akero Therapeutics Reports THIRD Quarter 2020 Financial Results
4:20pm
8-K
EX-99.1
5w1 zcihpbe
15 Oct 20
A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. Corporate Presentation October 2020
8:30am
8-K
EX-99.1
6xmulmw9wwkyw2xftyu
12 Aug 20
Akero Therapeutics Reports SECOND Quarter 2020 Financial Results
4:25pm
424B4
wvwwibakou gom
8 Jul 20
Prospectus supplement with pricing info
8:30pm
S-3
13j8 swyd
1 Jul 20
Shelf registration
4:08pm